A Study of Durvalumab (MEDI4736), as an Adjuvant Therapy, Compared to Observation Alone, in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma (BR PDA) Following Neoadjuvant Therapy and Successful Surgical Resection
Latest Information Update: 15 Sep 2020
At a glance
- Drugs Durvalumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 10 Sep 2020 Planned initiation date changed from 25 Dec 2017 to 12 Jun 2017.
- 10 Sep 2020 Planned End Date changed from 1 Dec 2019 to 1 Apr 2019.
- 10 Sep 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Apr 2019.